Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Lineage Cell Therapeutics Inc. Director's Dealing 2012

Jul 31, 2012

6895_dirs_2012-07-31_50fe0032-5be4-4bec-b4d4-cc8c097f5a1f.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOTIME INC (BTX)
CIK: 0000876343
Period of Report: 2012-07-30

Reporting Person: GREENWAY PARTNERS L P (10% Owner)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2012-07-30 Common Shares, no par value J 280000 $4.7661 Disposed 490373 Direct

Footnotes

F1: On July 30, 2012, Greenway transferred 280,000 BioTime common shares to BioTime's subsidiary LifeMap, Inc. in exchange for shares of LifeMap common stock under the terms of a Share Exchange and Contribution Agreement (the "LifeMap Agreement").

F2: Price determined under the LifeMap Agreement as the highest volume weighted average closing price per share on the NYSE MKT for ten consecutive trading days during the period from July 1, 2012 through July 31, 2012.